GENERAL, O. Reg. 201/96

Section 12.1

Cite as GENERAL, O. Reg. 201/96, s. 12.1 · current to November 11, 2026 · consolidated from July 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) The following conditions must be met in order for a designated listed drug product to continue to be designated as a listed drug product: 1. The manufacturer of the product shall give the executive officer notice of any change made to the product, including a formulation change, and of any change in the ownership of the manufacturer. 2. The product must be authorized for sale under the Food and Drugs Act (Canada). 3. The manufacturer of the product must continue to be able to supply the product at the drug benefit price in a quantity that is sufficient to meet the demand for the product. 4. Where the manufacturer was a party to an agreement to which this paragraph, as it read before October 1, 2006, applied, the manufacturer shall continue to be a party to that agreement until it expires according to its terms. 5. Subject to paragraphs 6.1 to 6.5, if the product has been designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act the drug benefit price of the product may not be more than the price that could be proposed to the executive officer under section 11 if a proposal was being made with respect to the drug product for the first time. 6. Revoked: O. Reg. 220/10, s. 4 (2). 6.1 Paragraph 5 does not apply with respect to a product that was designated as interchangeable with an original product on or before March 31, 2013, where there is evidence satisfactory to the executive officer that, i. the product is the only drug product of its type that is designated as interchangeable with an original drug product, and has been so designated for at least two years, and ii. removing the product’s listing would result in significant patient safety or access concerns, or significant increased costs to the Government of Ontario. 6.2 Paragraph 5 does not apply with respect to a product that has been designated as interchangeable with an original product where the manufacturer of the interchangeable product has submitted evidence satisfactory to the executive officer of substantial raw material cost increases or substantial direct manufacturing cost increases, and the executive officer is satisfied that the criteria established under section 12.2 have been met establishing that it is in the public interest that the interchangeable product be listed at a higher drug benefit price. 6.3 In the case of a drug product that was designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act before April 1, 2013, the drug benefit price of the product may not be more than the price that could have been proposed to the executive officer under section 11 as it read on March 31, 2013. 6.4 Despite paragraph 6.3, paragraph 5 applies to a drug product that was designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act before April 1, 2013 if, on or after April 1, 2018, i. another product is designated as interchangeable with the original product, or another product becomes interchangeable with the original product outside Ontario but within Canada, or ii. another product that was designated as interchangeable with the original product or another product that was interchangeable with the original product outside Ontario but within Canada is removed from the market. 6.5 When applying paragraph 5, the executive officer may adjust the drug benefit price of the original product upon which the drug benefit price of the interchangeable product is based, having regard to the price of the original product in other provinces and territories and to the historical drug benefit price of the original product on the Formulary or a price that was agreed to by the executive officer and the manufacturer under section 15. However, in doing so, the executive officer shall not change the actual drug benefit price of the original product on the Formulary. 6.6 Revoked: O. Reg. 436/19, s. 3 (2). 6.7 Revoked: O. Reg. 436/19, s. 3 (2). 6.8 Revoked: O. Reg. 436/19, s. 3 (2). 7. If required by the executive officer, the manufacturer of the product shall enter into and remain a party to an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: i. The name of the manufacturer. ii. The subject-matter of the agreement. iii. The fact of entering into or terminating the agreement. 8. If required by the executive officer, the manufacturer of a product that has been designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act shall inform the executive officer of the price that the manufacturer receives for the product, net of the value of any ordinary commercial terms. O. Reg. 459/06, s. 9; O. Reg. 559/06, s. 2 (1, 2); O. Reg. 320/07, s. 3 (1-4); O. Reg. 355/08, s. 3 (1-3); O. Reg. 220/10, s. 4 (1-4); O. Reg. 115/15, s. 2 (1-3); O. Reg. 436/19, s. 3 (1, 2). (2) For greater certainty, the conditions set out in subsection (1) apply whether the designation as a listed drug product or as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act took place before, on or after July 1, 2010. O. Reg. 459/06, s. 9; O. Reg. 220/10, s. 4 (5). (3) Where the circumstances described in paragraph 6.1 or 6.2 of subsection (1) exist, the executive officer may, in the executive officer’s sole discretion, negotiate an agreement with the manufacturer for any drug benefit price, but, (a) in no case may the interchangeable product be priced higher than the original product, unless, (i) the manufacturer has submitted detailed information to the executive officer demonstrating why the product should be priced higher than the original product, and (ii) the executive officer considers such a price to be in the public interest, having regard to the matters set out in subsection 22 (2) of the Act and to anything else the executive officer considers relevant; and (b) in respect of a product for which the only applicable circumstances are those set out in paragraph 6.1 of subsection (1), if the circumstance set out in subparagraph 6.1 i of subsection (1) no longer applies, the drug benefit price of the product shall revert to a price that is less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary on the date that the product was first proposed for designation as a listed drug product. O. Reg. 220/10, s. 4 (6). (4)-(7) Revoked: O. Reg. 436/19, s. 3 (3). (8) For the purposes of this section, in determining the price of an original product as of the applicable date, the executive officer may make the adjustments set out in subsection (9) in determining the price of the original product in the case of an interchangeable product, where, (a) the original product has not been a listed drug product or has not been sold in Ontario for at least 10 years; and (b) the interchangeable product is one of no more than two listed drug products that are designated as interchangeable with the original product. O. Reg. 115/15, s. 2 (4). (9) The adjustments mentioned in subsection (8) are as follows: 1. Determine the highest drug benefit price at which the original product was listed. 2. Commencing in the year in which the original product ceased to be listed or sold in Ontario, add an amount to reflect the average increase in consumer prices shown in Statistics Canada’s Consumer Price Index for Ontario (All Items) for each succeeding year to, i. a maximum of 10 years, or ii. a number of years determined by the executive officer that exceeds 10, where the executive officer is satisfied that it is in the public interest to make such a determination. O. Reg. 115/15, s. 2 (4). (10) Paragraphs 2 and 3 of subsection (1) do not apply with respect to a drug product or drug that is the subject of an exemption under subsection 12 (5.2). O. Reg. 436/19, s. 3 (4).
Read the GENERAL on e-Laws ↗

Made under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10.